Within first four months of 2018, seven new drugs are already approved by the FDA for a wide range of diseases including HIV, psoriasis, and rare cancers. 2018 will also see the first ever “game-changing” CRISPR gene editing clinical trial in humans.
Over the next five years, pharma giant, AstraZeneca will invest $90 million in India to improve the overall health outcomes in the country, by promoting innovation, skill development, and quality manufacturing.
Genprex raised $6.4 million in IPO at a share price of $5.
Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.
Big pharma players including Novartis, Roche, Pfizer, Sanofi are embracing digital technologies to deliver better to the patients.
FDA’S 2018 Strategic Policy Roadmap indicates increasing number of digital health clearances in coming times with revised regulatory processes.
The artificial intelligence (AI) based device called IDx-DR received US FDA approval for the screening of diabetic retinopathy- a common eye disease in diabetic patients that could lead to vision impairment and blindness.
Israeli startup Nutrino raised $8 million in their Series A funding round led by the existing investor New York Angels. According to the Medgenera report, the investment funding in health analytics is estimated to reach around $4.4 billion in 2018 at about 65.7% CAGR during 2015-2018.
Novartis bets high by acquiring the non-earning US-based gene therapy firm AveXis for $8.7 billion. But, AveXis' novel gene therapy- AVXS-101 could be a “game-changing” treatment for SMA patients and could turn out to be a potential blockbuster for Novartis, if approved.